ArticleJournal of neuro-oncology2019
Predicting disease progression in high-grade glioma with neuropsychological parameters: the value of personalized longitudinal assessment.
Article in Journal of neuro-oncology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 1 synthesis or guideline pooled it, 30 citations in OpenAlex.
- Factors affecting cognitive functions of patients with high-grade gliomas: a systematic review.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2023Pooled it
- Impact of High-Grade Glioma Lesion Location on Preoperative Neuropsychological Deficits.Cancers · 2025Article
- Neuropsychological Evaluation for Oncology.Neurologic clinics · 2024Review
- Predicting Cognitive Functioning for Patients with a High-Grade Glioma: Evaluating Different Representations of Tumor Location in a Common Space.Neuroinformatics · 2024Article
- Cognitive functioning in untreated glioma patients: The limited predictive value of clinical variables.Neuro-oncology · 2024Article
- The characteristics of auditorial event-related potential under propofol sedation associated with preoperative cognitive performance in glioma patients.Frontiers in neuroscience · 2024Article
- Letter regarding "Acceptability and feasibility of neurocognitive assessments with adults with primary brain cancer and brain metastasis: A systematic review".Neuro-oncology practice · 2023Article
- A Prospective Study of Longitudinal Risks of Cognitive Deficit for People Undergoing Glioblastoma Surgery Using a Tablet Computer Cognition Testing Battery: Towards Personalized Understanding of Risks to Cognitive Function.Journal of personalized medicine · 2023Article
- Digital participation of brain tumour patients in the assessment and treatment of communication disorders.Frontiers in psychology · 2023Article
- Mid-term treatment-related cognitive sequelae in glioma patients.Journal of neuro-oncology · 2022Article
- Presurgical predictors of early cognitive outcome after brain tumor resection in glioma patients.NeuroImage. Clinical · 2022Article
- Assessment of neurological function using the National Institute of Health Stroke Scale in patients with gliomas.Neuro-oncology practice · 2021Article
- Distributed changes of the functional connectome in patients with glioblastoma.Scientific reports · 2020Article
- Cognitive impairment three months after surgery is an independent predictor of survival time in glioblastoma patients.Journal of neuro-oncology · 2020Article
- Predicting cognitive function 3 months after surgery in patients with a glioma.Neuro-oncology advancesArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 1 country.
Funding
Abstract
purposeProgressive disease in patients with high-grade glioma may be reflected in cognitive decline. However, the cognitive functions most sensitive to progression may differ between patients. We investigated whether decline on a personalized selection of tests predicted progressive disease according to RANO criteria in high-grade glioma patients.
methodsStarting one day before surgery, patients underwent neuropsychological assessment every three months during standard treatment and clinical follow-up. We first made a personalized selection of three tests that showed the highest Reliable Change Index (RCI) values, i.e., most positive change, at the first post-surgical assessment for each patient. In subsequent follow up, a decline of RCI ≤ - 1 on at least two of the three tests in the selection was considered cognitive decline. We performed a discrete Cox proportional hazards model including a time-dependent coefficient cognitive decline (vs. stability) and covariate age to predict progressive disease.
resultsTwenty five patients were included. Cognitive decline on the personalized test selection preceded or had occurred by the time progression was established in 9/15 patients with RANO confirmed progressive disease (60%). Decline was absent in 8/10 patients (80%) with stable disease during participation. The independent hazard ratio for progression in case of cognitive decline was 5.05 (p < 0.01) compared to stable performance.
conclusionsUsing only three patient-specific neuropsychological tests, we found a fivefold increased chance of disease progression in case of cognitive decline as compared to stable performance. Brief, patient-tailored cognitive assessment may be a noninvasive addition to disease monitoring without overburdening patients and clinical care.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.